Table 3.

Subgroup analysis of medical fields, stratified by funding source, comparing OR of favorable primary outcome between intervention and control groups

Funding source	Cancer, OR (95% CI)	Cardiovascular, OR (95% CI)	Infectious disease, OR (95% CI)	Neurology, OR (95% CI)	Autoimmunity, OR (95% CI)	Diabetes, OR (95% CI)	Other, OR (95% CI)
Profit	1.89 (1.65–2.17)	1.83 (1.50–2.22)	1.96 (1.57–2.44)	2.12 (1.36–3.30)	4.34 (2.72–6.94)	1.86 (1.00–3.45)	2.52 (1.59–3.97)
Mixed funding	1.55 (1.26–1.90)	1.17 (1.03–1.20)a	1.45 (1.17–1.79)	1.57 (1.16–2.14)	1.46 (1.05–2.03)a	1.05 (0.91–1.20)	1.49 (0.96–2.07)
Nonprofit	1.13 (0.87–1.43)a	1.56 (1.37–1.76)b	1.33 (1.18–1.50)a	1.13 (0.97–1.32)a	2.39 (1.20–4.77)	1.12 (0.96–1.29)	1.31 (1.23–1.41)a

^aDenotes statistical difference compared with the for-profit funded studies (p < 0.05)

^bDenotes statistical difference compared with mixed funded studies (p < 0.05)